The oncomiR miR-197 is a novel prognostic indicator for non-small cell lung cancer patients.
The oncomiR miR-197 is a novel prognostic indicator for non-small cell lung cancer patients.
复制标题
DOI：
10.1038/bjc.2015.119
复制
发表时间：
2015-04-28
影响因子：
8.8
通讯作者：
Scorilas, A.
中科院分区：
文献类型：
--
作者：
Mavridis, K.;Gueugnon, F.;Petit-Courty, A.;Courty, Y.;Barascu, A.;Guyetant, S.;Scorilas, A.
MicroRNA 表达特征可以促进非小细胞肺癌 (NSCLC) 患者的个性化护理。我们的目的是评估 miR-197（一种非小细胞肺癌的关键致癌分子）之前未探索的预后潜力。使用 QIAsymphony SP 工作站进行总 RNA 分离（n=124 个 NSCLC 和 n=21 个肿瘤邻近正常组织）。通过分光光度分析和 Agilent 2100 生物分析仪评估 RNA 的数量和质量。随后进行多聚腺苷酸化和逆转录。在质量控制后，通过 qPCR 测量 MiR-197 表达水平（批间 CV=7.8%）。随后进行内部验证程序，分配训练和测试集，并进行稳健的生物统计分析，包括引导重采样。 MiR-197 与较大的肿瘤 (P=0.042) 和鳞状细胞癌组织型 (P=0.032) 相关。有趣的是，在调整重要的预后指标后，miR-197表达被确定为NSCLC患者不良预后的新型独立预测因子（HR=1.97，95% CI=1.10-3.38，P=0.013）。我们还证明 miR-197 在早期 I 期 (P=0.045) 和更晚期个体 (P=0.036) 中均保留其预后性能。 miR-197 的成本效益表达分析可以构成 NSCLC 管理的新型分子工具。
MicroRNA expression signatures can promote personalised care for non-small cell lung cancer (NSCLC) patients. Our aim was to evaluate the previously unexplored prognostic potential of miR-197, a key oncogenic molecule for NSCLC. Total RNA isolation (n=124 NSCLC and n=21 tumour-adjacent normal tissues), was performed using the QIAsymphony SP workstation. The quantity and quality of RNA were assessed by spectrophotometric analysis and an Agilent 2100 bioanalyzer. Polyadenylation and reverse transcription were subsequently carried out. MiR-197 expression levels were measured by qPCR, after quality control (inter-assay CV=7.8%). Internal validation procedures were followed by assigning training and test sets and robust biostatistical analyses were performed, including bootstrap resampling. MiR-197 is associated with larger tumours (P=0.042) and the squamous cell carcinoma histotype (P=0.032). Interestingly, after adjusting for important prognostic indicators, miR-197 expression was identified as a novel independent predictor of unfavourable prognosis for NSCLC patients (HR=1.97, 95% CI=1.10–3.38, P=0.013). We also demonstrate that miR-197 retains its prognostic performance in both early-stage I (P=0.045) and more advanced-stage individuals (P=0.036). The cost-effective expression analysis of miR-197 could constitute a novel molecular tool for NSCLC management.
登录
查看更多内容
影响因子：
45.3
作者：
Johnson, David H.;Schiller, Joan H.;Bunn, Paul A., Jr.
通讯作者：
Bunn, Paul A., Jr.
影响因子：
7.6
作者：
Estep, M.;Armistead, D.;Younossi, Z. M.
通讯作者：
Younossi, Z. M.
影响因子：
20.3
作者：
Liu, Cuiling;Iqbal, Javeed;Chan, Wing C.
通讯作者：
Chan, Wing C.
影响因子：
3.7
作者：
Lerman G;Avivi C;Mardoukh C;Barzilai A;Tessone A;Gradus B;Pavlotsky F;Barshack I;Polak-Charcon S;Orenstein A;Hornstein E;Sidi Y;Avni D
通讯作者：
Avni D
影响因子：
11.5
作者：
Keutgen, Xavier M.;Filicori, Filippo;Fahey, Thomas J., III
通讯作者：
Fahey, Thomas J., III